CD274 and cancer: Trastuzumab can enhance ICI efficacy through several immune-mediated mechanisms, such as activating natural killer cells, promoting intratumoral T cell infiltration, and upregulating PD-L1 and HLA-II expression in HER2-positive cancer cells [10–14].